Download
slide1 n.
Skip this Video
Loading SlideShow in 5 Seconds..
First Author 1 , Second Author 2 1 First Author’s Affiliation and 2 Second Author’s Affiliation PowerPoint Presentation
Download Presentation
First Author 1 , Second Author 2 1 First Author’s Affiliation and 2 Second Author’s Affiliation

First Author 1 , Second Author 2 1 First Author’s Affiliation and 2 Second Author’s Affiliation

197 Views Download Presentation
Download Presentation

First Author 1 , Second Author 2 1 First Author’s Affiliation and 2 Second Author’s Affiliation

- - - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

  1. Title, First Line Title, Second Line Poster number XXXX Author Information: Contacting Author Name Contacting Author e-mail Contacting Author mailing address Phone: (478) 301- XXXX Fax: (478) 301- XXXX First Author1, Second Author2 1First Author’s Affiliation and 2Second Author’s Affiliation Results Introduction Discussion Methods • Loremipsum dolor sit amet, consecteturadipiscingelit. Crastristiquemattis dolor bibendumeuismod. Nam semleo, ultricies vitae faucibussed, dignissimsednunc. Proin in diam id maurisconsequatmattisut at augue. Utvulputatenullaquisurnaconvallisfermentum. Aliquamnislleo, gravidaeusagittishendrerit, vehicula at urna. Maurisutliberonecnibhfermentumlacinia at at mauris. In in leogravidaestpretiummolestie. Donecinterdum nisi at risuslobortissagittis. Vivamus et libero nisi. Sedsedlectusodio, non bibendumjusto. Utvolutpat ante ac semrutrumvelfaucibusestlaoreet. Aliquamvulputatesodalesblandit. Quisque lacus libero, tempornecelementum ac, laciniatristiquemassa. Cras at tellusnisl. Mauris lacus dui, tinciduntegetplacerat ac, pretium a ligula. • Cras id lorem lacus, utmollisaugue. • Quisquesuscipitmollisadipiscing. • Etiamvolutpatscelerisquetortor in porta. • Aliquameratvolutpat. • Fuscedapibusmetus in nisi ornareullamcorper. • Proincommodoimperdietlorem id tempus. • Etiamnon nislodio. • Donecarculectus, mattisutbibendumvel, dignissimeumassa. Fusceeleifenddiam non velitlaciniaaliquam. Curabiturmaurissem, hendreritvelpharetra et, sodales ac erat. Fusce a diam in enimeuismodbibendum non id mauris. Fuscenectristiqueturpis. Aliquamtincidunturna a auguealiquet non laciniadiamcongue. Fuscesedmassa et tortorlobortispellentesque. Phasellustortorpurus, pretiumnecvarius a, accumsanutnisl. Mauris non ligula non nibhhendreritposuere. Integer ullamcorpertortor sit ameterostinciduntcongue. • Nuncut nisi neque, a vestibulumsapien. Vestibulum ante ipsumprimis in faucibusorciluctus et ultricesposuerecubiliaCurae; Mauriselementumrisus at puruslaoreetadipiscing. Vivamusauctorrisusenim. Curabiturauctorvehiculalacinia. Nunc at urnaerat. Aeneanfermentumauctoripsum id imperdiet. • Awesome • Conclusion • Here Loremipsum dolor sit amet, consecteturadipiscingelit. Crastristiquemattis dolor bibendumeuismod. Nam semleo, ultricies vitae faucibussed, dignissimsednunc. Proin in diam id maurisconsequatmattisut at augue. Utvulputatenullaquisurnaconvallisfermentum. Aliquamnislleo, gravidaeusagittishendrerit, vehicula at urna. Maurisutliberonecnibhfermentumlacinia at at mauris. In in leogravidaestpretiummolestie. Donecinterdum nisi at risuslobortissagittis. Vivamus et libero nisi. Sedsedlectusodio, non bibendumjusto. Utvolutpat ante ac semrutrumvelfaucibusestlaoreet. Aliquamvulputatesodalesblandit. Quisque lacus libero, tempornecelementum ac, laciniatristiquemassa. Cras at tellusnisl. Mauris lacus dui, tinciduntegetplacerat ac, pretium a ligula. Crasid lorem lacus, utmollisaugue. Quisquesuscipitmollisadipiscing. Etiamvolutpatscelerisquetortor in porta. Aliquameratvolutpat. Fuscedapibusmetus in nisi ornareullamcorper. Proincommodoimperdietlorem id tempus. Etiam non nislodio. Donecarculectus, mattisutbibendumvel, dignissimeumassa. Fusceeleifenddiam non velitlaciniaaliquam. Curabiturmaurissem, hendreritvelpharetra et, sodales ac erat. Fusce a diam in enimeuismodbibendum non id mauris. Fuscenectristiqueturpis. Aliquamtincidunturna a auguealiquet non laciniadiamcongue. Fuscesedmassa et tortorlobortispellentesque. Phasellustortorpurus, pretiumnecvarius a, accumsanutnisl. Mauris non ligula non nibhhendreritposuere. Integer ullamcorpertortor sit ameterostinciduntcongue. Nuncut nisi neque, a vestibulumsapien. Vestibulum ante ipsumprimis in faucibusorciluctus et ultricesposuerecubiliaCurae; Mauriselementumrisus at puruslaoreetadipiscing. Vivamusauctorrisusenim. Curabiturauctorvehiculalacinia. Nunc at urnaerat. Aeneanfermentumauctoripsum id imperdiet. Loremipsum dolor sit amet, consecteturadipiscingelit. Crastristiquemattis dolor bibendumeuismod. Nam semleo, ultricies vitae faucibussed, dignissimsednunc. Proin in diam id maurisconsequatmattisut at augue. Utvulputatenullaquisurnaconvallisfermentum. Aliquamnislleo, gravidaeusagittishendrerit, vehicula at urna. Maurisutliberonecnibhfermentumlacinia at at mauris. In in leogravidaestpretiummolestie. Donecinterdum nisi at risuslobortissagittis. Vivamus et libero nisi. Sedsedlectusodio, non bibendumjusto. Utvolutpat ante ac semrutrumvelfaucibusestlaoreet. Aliquamvulputatesodalesblandit. Quisque lacus libero, tempornecelementum ac, laciniatristiquemassa. Cras at tellusnisl. Mauris lacus dui, tinciduntegetplacerat ac, pretium a ligula. Cras id lorem lacus, utmollisaugue. Quisquesuscipitmollisadipiscing. Etiamvolutpatscelerisquetortor in porta. Aliquameratvolutpat. Fuscedapibusmetus in nisi ornareullamcorper. Proincommodoimperdietlorem id tempus. Etiam non nislodio. References Table 1. Title • Murphy RL, da Silva BA, Hicks CB, et al. Seven-year efficacy of a lopinavir/ritonavir-based regimen in antiretroviral –naïve HIV-1 infected patients. HIV Clin Trials 2008; 9:1-10 • Molina JM, Podsadecki TJ, Johnson MA, et al. A lopinavir/Ritonavir based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 weeks. AIDS Res Hum Retroviruses 2007;23:1505-14 • Schechter M, Nunes EP. Monotherapy with lopinavir/ritonavir.Expert Opin Investig Drugs 2007; 16(5): 735-41 • Zuger A. Report from the XVI International AIDS Conference. Lopinavir/ritonavir monotherapy. AIDS Clin Care 2006; 18: 99-100 • Pierone G Jr., Mieras J, Bulgin-Coleman G, et al. A pilot study of switch to lopinavir/ritonavir (LPV/r) monotherapy from nonnucleoside reverse transcriptase inhibitor-based therapy. HIV Clin Trials 2006; 7: 237-45. • Arribas JR, PulidoF, DelgadoR, et al. Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study). J Acquir Immune Defic Syndr 2005; 40:280-7 Acknowledgements Thank You, Thank You, Thank You!